Sunday, January 29, 2023

Tag: Alzheimer’s treatment

Ethical Issues Raised Over FDA Collaboration with Biogen on Failed Drug

7
The FDA collaborated with Biogen to conduct repeated re-analyses of aducanumab for Alzheimer's and FDA committee members are raising concerns.

Biogen Pushes FDA to Approve Failed Alzheimer’s Drug

2
A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.